Press Releases
1303, 2020
FDA Grants Breakthrough Therapy Designation to JNJ-6372 in mNSCLC
This Breakthrough Therapy designation is supported by results from a phase I, first-in-human study of JNJ- 61186372, ...as monotherapy and in combination with novel third generation EGFR tyrosine kinase inhibitor (TKI) lazeritinib...
611, 2018
Yuhan signs $1.25 billion licensing deal with Janssen
Lasertinib(GNS-1480), discovered by Genosco, was out-licensed to Janssen.
306, 2018
Early results from a 3rd gen EGFR-TKI in advanced NSCLC
Dr. Cho speaks with ecancer at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting about a phase I/II trial of lazertinib(GNS-1480, YH25448), a highly selective and irreversible investigational 3rd-generation EGFR-TKI.
1605, 2018
Genosco/Yuhan Announce Results from Phase 1/2 Study of YH25448(GNS-1480), a 3rd-Generation EGFR-TKI, in Advanced NSCLC to be Presented at ASCO 2018
Business Wire * May 16, 2018; Abstract - https://meetinglibrary.asco.org/record/161036/abstract